Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367640
Status:
COMPLETED
Last Update Posted:
2016-05-23
First Post:
2006-08-22
Brief Title:
Safety and Efficacy of Sublingual Immunotherapy SLIT Tablets in Grass Pollen Rhinoconjunctivitis
Sponsor:
Stallergenes Greer
Organization:
Stallergenes Greer
Study Overview
Official Title:
RandomisedDouble-blindPlacebo-controlledMultinationalMulti-centrePhase IIbIII Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy SLIT Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of SLIT compared with placebo for reduction of symptoms and rescue medication usage
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None